Trial · NCT04875611
Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment
NCT04875611, Phase 2, Recruiting, Maria Sklodowska-Curie National Research Institute of Oncology
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment. Trials, record NCT04875611. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04875611
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment
- NCT number
- NCT04875611
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 32 participants, estimated
- Lead sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
- Conditions
- Nasopharyngeal Cancer
- Interventions
- Opdivo
- First posted
- 2021-05-06
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate (ORR) | 12 weeks | Percentage of objective responses (partial and complete responses combined /partial response (PR)+ complete response(CR)/ by immune Response Evaluation Criteria in Solid Tumours (iRECIST) response criteria) in MRI (Magnetic Resonance Imaging) after 12 weeks. 1. Partial response - at least a 30% decrease in the sum of the LD(longest diameter) of target lesions, taking as reference the baseline sum LD(longest diameter) 2. Complete response (CR)- disappearance of all target lesions and short dimension of all lymph nodes \< 10 mm |
| Secondary | 1.Progression- free survival (PFS) by iRECIST( immune Response Evaluation Criteria in Solid Tumours) criteria- from the beginning of treatment to the progression of disease or death. | 6 month of treatment phase | Progression will be evaluated in MRI(Magnetic Resonance Imaging) and defined according to iRECIST(immune Response Evaluation Criteria in Solid Tumours) criteria: * least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) and the sum must also demonstrate an absolute increase of at least 5 mm. * the appearance of one or more new lesions |
| Secondary | Overall survival (OS) rate- time of total survival | at 6 months (treatment phase), 12 months and 18 months (6th month and 12th month of long term follow up) | |
| Secondary | DCR(disease control rate) per RECIST (Response Evaluation Criteria in Solid Tumours) | through study completion, an average of 6 months | Defined as not meeting the criteria for progression and PR(partial response) |
| Secondary | DoR(duration of response) per RECIST (Response Evaluation Criteria in Solid Tumours) | through study completion, an average of 1 year | Measured in MRI(Magnetic Resonance Imaging) from the time when measurement criteria for complete/ partial response are met till time when progression of the disease is documented. |
| Secondary | Change in quality of life in EORTC QLQ-C30(European Organization for Research and Treatment of Cancer Quality of Life Questionnaire) (version 3.0) .A high scale score represents a higher response level. | from first infusion to last follow up ( 3 month, 6 month, 9 month,12month follow up) | |
| Secondary | Safety assessment of treatment with Nivolumab measured by excesive toxity | Each visit during treatment phase -12 cycles of investigation product's infusion (around 6 month of treatment). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04875611
GET https://conductscience.org/api/trials/v1/NCT04875611/registered